A new angle on Notch combination therapies

To develop cancer therapies based on modulating “ivy league” signaling pathways such as Wnt, BMP/TGFβ, Sonic Hedgehog and Notch signaling is a research avenue currently attracting considerable interest both from academia and industry. In a recent report by Ambrogio et al. in Nature Medicine (1), the authors provide evidence that a combination therapy based on simultaneously targeting the Notch signaling pathway and the DDR1 kinase may be an interesting approach towards novel therapy development for lung cancer.